Evidence map›Paper›PMID 40641450›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Advanced Microfluidics for Single Cell-Based Cancer Research.

Adriana Carneiro, Marta Aranda Palomer, Margarida Esteves, Carolina Rodrigues, José Maria Fernandes, Francisca Oliveira, Alexandra Teixeira, Carlos Honrado, Lorena Dieguez, Sara Abalde-Cela and 1 more

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Molecules (Basel, Switzerland) · 2026
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Advanced Microfluidics for Single Cell-Based Cancer Research.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Adriana CarneiroINL - International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, s/n, Braga, 4715-330, Portugal.ORCID https://orcid.org/0000-0003-1905-6250
Marta Aranda PalomerINL - International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, s/n, Braga, 4715-330, Portugal.ORCID https://orcid.org/0000-0001-7949-9614
Margarida EstevesINL - International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, s/n, Braga, 4715-330, Portugal.ORCID https://orcid.org/0000-0002-3091-0916
Carolina RodriguesINL - International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, s/n, Braga, 4715-330, Portugal.ORCID https://orcid.org/0000-0002-0303-9125
José Maria FernandesINL - International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, s/n, Braga, 4715-330, Portugal.ORCID https://orcid.org/0009-0003-1385-3133
Francisca OliveiraINL - International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, s/n, Braga, 4715-330, Portugal.ORCID https://orcid.org/0009-0002-0977-7927
Alexandra TeixeiraINL - International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, s/n, Braga, 4715-330, Portugal.ORCID https://orcid.org/0000-0002-5685-625X
Carlos HonradoINL - International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, s/n, Braga, 4715-330, Portugal.ORCID https://orcid.org/0000-0002-4151-2147
Lorena DieguezINL - International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, s/n, Braga, 4715-330, Portugal.ORCID https://orcid.org/0000-0003-3695-6963
Sara Abalde-CelaINL - International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, s/n, Braga, 4715-330, Portugal.ORCID https://orcid.org/0000-0001-5615-594X
Miguel XavierINL - International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, s/n, Braga, 4715-330, Portugal.ORCID https://orcid.org/0000-0002-0447-5439

Funding

Fundação para a Ciência e a Tecnologia 2021.05593.BDH2020 Future and Emerging Technologies 965018HORIZON EUROPE European Innovation Council 101099066HORIZON EUROPE Marie Sklodowska-Curie Actions 101069074UK Research and Innovation 10063360
6 · The paper itself

Abstract

Cancer remains one of the leading causes of mortality worldwide, accounting for ≈10 million deaths annually. Critically, it is metastasis and not the primary tumour that causes most of these deaths. Understanding the mechanisms behind cancer dissemination and therapy resistance is thus a pressing challenge. Traditional bulk tissue analyses have failed to capture the full spectrum of intra-tumour heterogeneity and the dynamic interactions within the tumour microenvironment. Studying cancer at the single-cell level allows unravelling the roles of rare subpopulations, cell-cell interactions, and spatial dynamics that govern tumour evolution, metastasis, and immune evasion. This review explores how recent advances in microfluidic technologies are transforming ability to model and study cancer at the single-cell level. Cutting-edge platforms are highlighted, including droplet microfluidics, single cell-derived spheroids, and tumour-chips, that enable physiologically relevant 3D cancer models. By integrating immune components, biosensing, and patient-derived materials, these platforms hold promise for advancing drug screening, immunotherapy assessment, and personalised medicine. It is concluded by identifying key challenges and priorities for future work, which should focus on increasing model complexity, reproducibility, and integration of spatiotemporal multiomics to better dissect tumour heterogeneity and accelerate clinical translation.

Indexed as

MicrofluidicsNeoplasmsSingle-Cell AnalysisAnimalsHumansTumor Microenvironment3D modelsmicrofluidicsmulti‐omicsorgan‐on‐chipsingle‐cell technologies

Identifiers

PMID40641450
PMCPMC12591218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.